Overview

• The multi-center Phase I/II CADENZA trial enrolled 84 BPDCN patients receiving PVEK every 21 days in both frontline and relapsed or refractory settings.
• Frontline participants achieved an 85% overall response rate, with 70% attaining complete remissions.
• PVEK employs a monoclonal antibody linked to a cytotoxic payload to selectively target CD123-expressing BPDCN cells.
• The most common side effect was reversible peripheral edema, offering a more manageable safety profile compared with capillary leak syndrome associated with tagraxofusp-erzs.
• Led by MD Anderson researchers and funded by AbbVie, the study paves the way for PVEK’s exploration in combination therapies and potential adoption as a new treatment standard.